IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 52.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 612 shares of the medical research company’s stock after selling 675 shares during the quarter. Salem Investment Counselors Inc.’s holdings in IQVIA were worth $155,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of IQV. Norges Bank acquired a new position in IQVIA during the 4th quarter valued at approximately $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after acquiring an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC boosted its holdings in shares of IQVIA by 96.9% in the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock valued at $286,704,000 after acquiring an additional 606,333 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of IQVIA by 42.2% in the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock valued at $461,675,000 after acquiring an additional 592,372 shares during the last quarter. Finally, Cadian Capital Management LP purchased a new stake in shares of IQVIA in the 4th quarter valued at $70,108,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IQV. Truist Financial dropped their price objective on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Robert W. Baird dropped their price objective on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a report on Friday, May 3rd. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Friday. Leerink Partnrs reissued an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, Evercore ISI lowered their price target on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a report on Friday, May 3rd. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $258.40.

IQVIA Price Performance

Shares of NYSE IQV opened at $216.25 on Monday. The firm has a 50-day simple moving average of $225.57 and a 200-day simple moving average of $230.38. The stock has a market capitalization of $39.40 billion, a price-to-earnings ratio of 29.54, a price-to-earnings-growth ratio of 1.95 and a beta of 1.53. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The business had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.